Purapharm Corp Ltd (1498) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Purapharm Corp Ltd stock HK$0.58, price HK$0.24, upside +146.0%, quality 30 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value 30%+ above price?Yes
Quality 50+?No
In an uptrend?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 24, 2026.
How to read this chart
60‑month range HK$0.2350 – HK$1.85 · fair‑value band HK$0.4080 – HK$0.7395 · the HK$0.2350 price screens below the HK$0.5780 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 24, 2026.
Follow Purapharm Corp in your weekly email
Every Wednesday you see whether Purapharm Corp is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally.
Show moreShow less
It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names.
It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provides Chinese medicine services and CCMG products.
In addition, the company engages in the plantation and trading of raw Chinese herbs; manufacture and sale of traditional Chinese medicine decoction pieces; provision of modernized Chinese medicine services, Chinese medical diagnostic services; and research and development of new products and bio-based polymeric materials.
Further, It operates an online platform. PuraPharm Corporation Limited was incorporated in 1998 and is headquartered in Tai Po, Hong Kong.
Stock analysis
Purapharm Corp Ltd (1498) currently trades at HK$0.2350, while our model-based Fair Value estimate is HK$0.5780, implying the stock looks roughly 59.3% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of HK$0.6900 per share, and 8 of the 10 models we run sit above the HK$0.2350 price.
Bear case: the Asset-Based group reads lowest at HK$0.0600, and 2 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$0.4080 (bear) to HK$0.7395 (bull), the price of HK$0.2350 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Purapharm Corp Ltd reported revenue of HK$336M in FY2025 versus HK$660M in FY2021, a compound −15.5%/yr. Reported net income was −HK$35.2M in FY2025.
Key figures
Market cap HK$126M (≈ $16.0M) Micro · P/S ratio 0.42 · Net margin −10.5% · Return on equity −24.4% · Return on assets (EBIT) −3.9% · Operating margin −4.3% · Revenue (TTM) HK$323M · Revenue growth (YoY) −7.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 44% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at 146%, 1498 screens cheaper than that median.
Fair Value models
BearHK$0.4080Fair Value HK$0.5780BullHK$0.7395
Price HK$0.2350 · Upside +146.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCFHK$0.7000HK$1.00HK$1.5680
Growth DCFHK$0.7400HK$1.03HK$1.5378
Owner EarningsHK$0.3800HK$0.5500HK$0.870076
All 10 models by family
DCF Models
FCF DCFHK$0.7000HK$1.00HK$1.5680
Owner EarningsHK$0.3800HK$0.5500HK$0.870076
5Y Revenue ExitHK$0.4800HK$0.6800HK$0.970073
5Y EBITDA ExitHK$0.3800HK$0.5100HK$0.680076
10Y Revenue ExitHK$0.5500HK$0.7000HK$0.870068
10Y EBITDA ExitHK$0.5000HK$0.6000HK$0.700070
Multiples
EV/Revenuen/aHK$0.0100>HK$0.040050
Asset-Based
NCAV (Graham)HK$0.0400HK$0.0600HK$0.090053
Growth DCF
Growth DCFHK$0.7400HK$1.03HK$1.5378
Rev-Margin DCFHK$0.4800HK$0.6900HK$0.970073
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.0%
Start year 2020 (pandemic). Over 10 years: −3.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.8% (2020) → −8.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +2.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 579 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score30 · Bottom 25%
Fair Value upside+146.0% · Top 25%
Profitability
Return on assets−5.1% · Bottom 25%
Net margin (12 months)−8.6% · Bottom 25%
Operating margin (12 months)−4.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−7.3% · Below median
Balance sheet
Debt / equity0.43× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Purapharm Corp Ltd (1498) overvalued or undervalued?
As of Oct 24, 2026, our model estimates a fair value of HK$0.5780 versus a price of HK$0.2350, about +146% upside (undervalued).
What is the fair value of 1498?
Our model-based fair value for Purapharm Corp Ltd is HK$0.5780 (as of Oct 24, 2026), built from audited fundamentals. The current price: HK$0.2350.
What is the quality score of 1498?
Purapharm Corp Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Purapharm Corp Ltd (1498)?
Our model-based price target is the fair value of HK$0.5780 (as of Oct 24, 2026) from 10 valuation models. Cautious scenario HK$0.4080, optimistic scenario HK$0.7395. It is a calculation from audited fundamentals, not an analyst target.
What is the Purapharm Corp Ltd stock forecast for 2026?
Our models put fair value at HK$0.5780, about +146% upside versus a price of HK$0.2350 (undervalued). Cautious scenario HK$0.4080, optimistic scenario HK$0.7395. The calculation is refreshed regularly with new filings.
What is the revenue of Purapharm Corp Ltd (1498)?
Purapharm Corp Ltd reported trailing-twelve-month revenue of about HK$323M (latest available figure, as of Oct 24, 2026).
What growth is priced into Purapharm Corp Ltd (1498)?
For today's price to be fair in a discounted-cash-flow model, Purapharm Corp Ltd would have to grow free cash flow by +4.4 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -11.0 % per year. As of Oct 24, 2026.
What discount rate (WACC) does the fair value of 1498 use?
Our models discount Purapharm Corp Ltd at 9.0 %: a base by market capitalisation (nano), damped by beta 0.20, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Purapharm Corp Ltd that is +4.4 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Purapharm Corp Ltd (1498) delivered so far?
Over the past 5 years revenue at Purapharm Corp Ltd grew -11.0 % a year. The price currently implies +4.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Purapharm Corp Ltd (1498) growing?
The median revenue growth in the sector is +6.1 % a year. That is the yardstick for the growth priced into Purapharm Corp Ltd (+4.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Purapharm Corp Ltd (1498)?
The free-cash-flow yield on the price is 20.43 %: that much free cash flow Purapharm Corp Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Purapharm Corp Ltd (1498)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Purapharm Corp Ltd it is HK$0.5780 per share (as of Oct 24, 2026), against a price of HK$0.2350. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Purapharm Corp Ltd stock overvalued or undervalued in 2026?
As of Oct 24, 2026, 1498 trades below its calculated fair value: price HK$0.2350, fair value HK$0.5780, a gap of about +146% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1498?
No. The price is what the market pays today (HK$0.2350); the fair value is what the company's own numbers justify (HK$0.5780). For Purapharm Corp Ltd the two are HK$0.3430 per share apart. That gap is exactly why we show both numbers side by side.
How much is Purapharm Corp Ltd worth?
The market values Purapharm Corp Ltd at about HK$126M (market capitalisation, as of Oct 24, 2026). Per share that is HK$0.2350; our models calculate a fair value of HK$0.5780 per share.
What do the bullish and bearish scenarios say about 1498?
Our models span a range for Purapharm Corp Ltd: cautious scenario HK$0.4080, base HK$0.5780, optimistic HK$0.7395 per share (as of Oct 24, 2026, price HK$0.2350). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Purapharm Corp Ltd (1498)?
Balance-sheet figures for Purapharm Corp Ltd (as of Oct 24, 2026): return on equity −24.4%, debt of 0.43 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 1498 from its 52-week high?
Purapharm Corp Ltd trades at HK$0.2350, about 44% below its 52-week high of HK$0.4200 and at the low of HK$0.2350 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.5780 is for.
Which stocks are comparable to Purapharm Corp Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Purapharm Corp Ltd stock attractive at the current price?
The data as of Oct 24, 2026: price HK$0.2350, calculated fair value HK$0.5780 (+146%), Quality Score 30/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1498 calculated?
We run Purapharm Corp Ltd through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.5780, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Purapharm Corp Ltd currently trades 59 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Purapharm Corp Ltd (1498)?
The closing price on Oct 28, 2026 was HK$0.2350. Our model-based fair value is HK$0.5780, about +146% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Purapharm Corp Ltd right now?
The large discount to fair value meets weak quality (30/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (HK$0.4080). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.4080 to HK$0.7395) leaves room in how you read the outcome.
Key figures of Purapharm Corp Ltd
How large is the market capitalisation of Purapharm Corp Ltd (1498)?
The market capitalisation of Purapharm Corp Ltd is HK$126M (≈ $16.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Purapharm Corp Ltd (1498)?
The price-to-sales ratio of Purapharm Corp Ltd is 0.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Purapharm Corp Ltd (1498)?
The net margin of Purapharm Corp Ltd is −10.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Purapharm Corp Ltd (1498)?
The return on equity (ROE) of Purapharm Corp Ltd is −24.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Purapharm Corp Ltd (1498)?
On an EBIT basis the return on assets of Purapharm Corp Ltd is −3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Purapharm Corp Ltd (1498)?
The operating margin of Purapharm Corp Ltd is −4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Purapharm Corp Ltd (1498)?
Revenue at Purapharm Corp Ltd is growing −7.3% versus a year earlier (3y avg −9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Purapharm Corp Ltd (1498)?
Earnings per share at Purapharm Corp Ltd are growing −7.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Purapharm Corp Ltd (1498) carry?
The net debt of Purapharm Corp Ltd is HK$330M (fiscal year 2025, ≈ 12.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Purapharm Corp Ltd in the live analysis
One click puts Purapharm Corp Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 24, 2026